Inherited thrombophilia and gestational vascular complications

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 2, 2003, Pages 321-332

  Grandone, Elvira ^a   Margaglione, Maurizio ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Fetal loss; Hyperhomocysteinaemia; Pre eclampsia; Pregnancy complications; Pregnancy outcome; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; WARFARIN; ANTICOAGULANT AGENT;

CASE CONTROL STUDY; CLINICAL OBSERVATION; CLINICAL TRIAL; DISEASE ASSOCIATION; FEMALE; FETUS WASTAGE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; INTRAUTERINE GROWTH RETARDATION; LONGITUDINAL STUDY; MATERNAL HYPERTENSION; MEDICAL LITERATURE; PREECLAMPSIA; PREGNANCY DISORDER; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; SIDE EFFECT; THROMBOEMBOLISM; THROMBOPHILIA; TREATMENT OUTCOME; VASCULAR DISEASE; BLOOD CLOTTING; INHERITANCE; PREGNANCY COMPLICATION; VENOUS THROMBOEMBOLISM;

EID: 0038317610     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(03)00017-3     Document Type: Review

References (51)

1. Mousa HA & Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Human Reproduction 2000; 15: 1830-1833.
2. Stirrat GM. Recurrent miscarriage I: definition and epidemiology. Lancet 1990; 336: 673-675.
3. Göpel W, Ludwig M, Junge AK et al. Selection pressure for the factor V Leiden mutation and embryo implantation. Lancet 2001; 358: 1238-1239.
4. Grandone E, Colaizzo D, Lo Bue A et al. Inherited thrombophilia and in vitro fertilization implantation failure. Fertility & Sterility 2001; 76: 201-202.
5. Juul K, Tybærg-Hansen A & Nordestgaard BG. Factor V Leiden: relation to fertility? Lancet 2002; 359: 894.
6. James DK, Steer PJ & Weiner CP (eds) High Risk Pregnancy-Management Options. London: WB Saunders, London 1994, pp 253-255.
7. Sibai BM. Hypertensive disease. In Gleicher N (ed.) Principle and Practice of Medical Therapy in Pregnancy. Stamford, CT: Appleton and Lange, 1998, pp 997-1022.
8. Lyall F & Greer IA. Preeclampsia: a multifaceted vascular disorder of pregnancy. Journal of Hypertension 1994; 12: 1339-1345.
9. Atrash HK, Koonin L, Lawson HW et al. Maternal mortality in the United States, 1979-1986. Obstetrics & Gynecology 1990; 76: 1055-1060.
10. Eskenazi B, Fenster L & Sidney S. A multivariate analysis of risk factors for preeclampsia. JAMA 1991; 266: 237-241.
11. Mostello D, Catlin TK, Roman L et al. Preeclampsia in the parous woman: who is at risk? American Journal of Obstetrics and Gynecology 2002; 187: 425-429.
12. Redman CWG. Current topic: pre-eclampsia and the placenta. Placenta 1991; 12: 301-308.
13. Redman CWG. Platelets and the beginning of pre-eclampsia. New England Journal of Medicine 1990; 323: 478-480.
14. Greer IA. Pathological processes in pregnancy-induced hypertension and intrauterine growth retardation: 'an excess of heated blood'. In Greer IA, Turpie AGG & Forbes CD (eds) Haemostasis and Thrombosis in Obstetrics and Gynaecology. London: Chapman and Hall, 1992, pp 163-202.
15. Dekker GA, Vries JIP, Doelitzsch PM et al. Underlying disorders associated with severe early-onset preeclampsia. American Journal of Obstetrics and Gynecology 1995; 173: 1042-1048.
16. van Pampus M, Dekker GA, Wolf H et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. American Journal of Obstetrics and Gynecology 1999; 180: 1146-1150.
17. de Vries JI, Dekker GA, Huijgens PC et al. Hyperhomocysteinemia and protein S deficiency in complicated pregnancies. British Journal of Obstetrics and Gynaecology 1997; 104: 1248-1254.
18. Dizon-Townson DS, Nelson LM, Easton K & Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. American Journal of Obstetrics and Gynecology 1996; 175: 902-905.
19. Grandone E, Margaglione M, Colaizzo D et al. Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to pre-eclampsia. Thrombosis & Haemostasis 1997; 77: 1052-1054.
20. Lindoff C, Ingermarsson I, Martinsson G et al. Pre-eclampsia is associated with a reduced response to activated protein C. American Journal of Obstetrics and Gynecology 1997; 176: 457-460.
21. Kupferminc MJ, Eldor A, Steinman N et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. New England Journal of Medicine 1999; 340: 9-13.
22. Grandone E, Margaglione M, Colaizzo D et al. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thrombosis & Haemostasis 1999; 81: 349-352.
23. De Groot CJM, Bloemenkamp KWM, Duvekot EJ et al. Preeclampsia and genetic risk factors for thrombosis: a case-control study. American Journal of Obstetrics and Gynecology 1999; 181: 975-980.
24. Livingston JC, Barton JR, Park V et al. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. American Journal of Obstetrics and Gynecology 2001; 185: 153-157.
25. Martinelli P, Grandone E, Colaizzo D et al. Familial thrombophilia and the occurrence of fetal growth restriction. Haematologica 2001; 86: 428-431.
26. Khong TY & Hague WM. Biparental contribution to fetal thrombophilia in discordant twin intrauterine growth restriction. American Journal of Obstetrics and Gynecology 2001; 185: 244-245.
27. Clark P, Walker ID & Greer I. Acquired activated protein-C resistance and association with increased thrombin generation and fetal weight. Lancet 1999; 353: 292-293.
28. Gopel W, Kim D & Gortner L. Prothrombotic mutations as a risk factor for pretem birth. Lancet 1999; 353: 1411-1412.
29. von Kries R, Junker R, Oberle D et al. Foetal growth restriction in children with prothrombotic risk factors. Thrombosis & Haemostasis 2001; 86: 1012-1016.
30. Infant-Rivard C, Rivard GE, Yotov W et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. New England Journal of Medicine 2002; 347: 19-25.
31. Ridker PM, Miletich JP, Hennekens CH & Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. JAMA 1997; 277: 1305-1307.
32. Grandone E, Margaglione M, Colaizzo D et al. Lower birth-weight in neonates of mothers carrying factor V G1691A and factor II A(20210) mutations. Haematologica 2002; 87: 177-181.
33. Grandone E, Colaizzo D, Brancaccio V et al. Impact of prothrombotic mutations and family history on the occurrence of intra-uterine fetal deaths. Haematologica 2002; 87: 1118-1119.
34. Dekker GA, de Vries JI, Doelitzsch PM et al. Underlying disorders associated with severe early onset of pre-eclampsia. American Journal of Obstetrics and Gynecology 1995; 173: 104-145.
35. Rajkovic A, Catalano PM & Malinow MR. Elevated homocyst(e)ine levels with pre-eclampsia. Obstetrics & Gynecology 1997; 90: 168-171.
36. Rajkovic A, Mahomed K, Malinow R et al. Plasma homocyst(e)ine concentrations in eclamptic and pre-eclamptic african women postpartum. Obstetrics & Gynecology 1999; 94: 355-360.
37. Gindler J, Li Z, Berry RJ etal. Folic acid supplements during pregnancy and risk of miscarriage. Lancet 2001; 358: 796-800.
38. Quéré I, Mercier E, Bellet H et al. Vitamin supplementation and pregnancy outcome in women with recurrent early pregnancy loss and hyperhomocysteinemia. Fertility & Sterility 2001; 75: 823-825.
39. Vollset SE, Refsum H, Irgens LM et al. Plasma total homocysteine, pregnancy complications, and adverse obstetric outcomes: the Hordaland Homocysteine Study. American Journal of Clinical Nutrition 2000; 71: 962-968.
40. Hietala R, Turpeinen U & Laatikainen T. Serum homocysteine at 16 weeks and subsequent preeclampsia. Obstetrics & Gynecology 2001; 97: 527-579.
41. Cotter AM, Molloy AM, Scott JM & Daly SF. Elevated plasma homocysteine in early pregnancy: a risk factor for the development of severe preeclampsia. American Journal of Obstetrics and Gynecology 2001; 185: 781-785.
42. Nelen WLDM, Blom HJ, Steegers; EA et al. Homocysteine and folate levels as risk factors for recurrent early pregnancy loss. Obstetrics & Gynecology 2000; 95: 519-524.
43. Hogg BB, Tamura T, Johnston KE et al. Second-trimester plasma homocysteine levels and pregnancy-induced hypertension, preeclampsia, and intrauterine growth restriction. American Journal of Obstetrics and Gynecology 2000; 183: 805-809.
44. Nelen WL, Blom HJ, Steegers EA et al. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertility & Sterility 2000; 76: 1196-1199.
45. Nelen WLDM, Steegers EAP, Eskes TK Genetic risk factor for unexplained recurrent early pregnancy loss. Lancet 1997; 350: 861.
46. Kutteh WH, Park VM & Deitcher SR. Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. Fertility & Sterility 1998; 71: 1048-1053.
47. Grandone E, Margaglione M, Colaizzo D et al. Methylene tetrahydrofolate reductase (MTHFR) 677T C mutation and unexplained early pregnancy loss. Thrombosis & Haemostasis 1998; 79: 1056-1057.
48. Ginsberg JS, Greer I & Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119: 122S-131S.
49. Younis JS, Ohel G, Brenner B et al. The effect of thromboprophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. British Journal of Obstetrics and Gynaecology 2000; 107: 415-419.
50. Brenner B, Hoffman R, Blumenfeld Z et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thrombosis & Haemostasis 2000; 83: 693-697.
51. Grandone E, Brancaccio V, Colaizzo D et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertility & Sterility 2002; 78: 371-375.